Injectable Polyethylene Glycol Biomaterial Market Report – Research, Industry Analysis Reports and Market Demands

Global Injectable Polyethylene Glycol Biomaterial Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Fast-Setting Type (Seconds – 1 Minute)
- 1.3.3 Medium-Setting Type (1–10 Minutes)
- 1.3.4 Slow-Setting Type (Over 10 Minutes)
1.4 Market Analysis by Molecular Weight
- 1.4.1 Overview: Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Molecular Weight: 2021 Versus 2025 Versus 2032
- 1.4.2 Low Molecular Weight PEG
- 1.4.3 Medium Molecular Weight PEG
- 1.4.4 High Molecular Weight PEG
1.5 Market Analysis by Degradability
- 1.5.1 Overview: Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Degradability: 2021 Versus 2025 Versus 2032
- 1.5.2 Non-Degradable Type
- 1.5.3 Slowly Degradable Rype
- 1.5.4 Controllably Degradable Type
- 1.5.5 Rapidly Degradable Type
1.6 Market Analysis by Application
- 1.6.1 Overview: Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.6.2 Biopharmaceutical Industry
- 1.6.3 Medical Aesthetics Industry
- 1.6.4 Implant Material Supporting Industry
- 1.6.5 Others
1.7 Global Injectable Polyethylene Glycol Biomaterial Market Size & Forecast
- 1.7.1 Global Injectable Polyethylene Glycol Biomaterial Consumption Value (2021 & 2025 & 2032)
- 1.7.2 Global Injectable Polyethylene Glycol Biomaterial Sales Quantity (2021-2032)
- 1.7.3 Global Injectable Polyethylene Glycol Biomaterial Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Injectable Polyethylene Glycol Biomaterial by Manufacturer

3.1 Global Injectable Polyethylene Glycol Biomaterial Sales Quantity by Manufacturer (2021-2026)
3.2 Global Injectable Polyethylene Glycol Biomaterial Revenue by Manufacturer (2021-2026)
3.3 Global Injectable Polyethylene Glycol Biomaterial Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Injectable Polyethylene Glycol Biomaterial by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Injectable Polyethylene Glycol Biomaterial Manufacturer Market Share in 2025
- 3.4.3 Top 6 Injectable Polyethylene Glycol Biomaterial Manufacturer Market Share in 2025
3.5 Injectable Polyethylene Glycol Biomaterial Market: Overall Company Footprint Analysis
- 3.5.1 Injectable Polyethylene Glycol Biomaterial Market: Region Footprint
- 3.5.2 Injectable Polyethylene Glycol Biomaterial Market: Company Product Type Footprint
- 3.5.3 Injectable Polyethylene Glycol Biomaterial Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Injectable Polyethylene Glycol Biomaterial Market Size by Region
- 4.1.1 Global Injectable Polyethylene Glycol Biomaterial Sales Quantity by Region (2021-2032)
- 4.1.2 Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Region (2021-2032)
- 4.1.3 Global Injectable Polyethylene Glycol Biomaterial Average Price by Region (2021-2032)
4.2 North America Injectable Polyethylene Glycol Biomaterial Consumption Value (2021-2032)
4.3 Europe Injectable Polyethylene Glycol Biomaterial Consumption Value (2021-2032)
4.4 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Consumption Value (2021-2032)
4.5 South America Injectable Polyethylene Glycol Biomaterial Consumption Value (2021-2032)
4.6 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
5.2 Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Type (2021-2032)
5.3 Global Injectable Polyethylene Glycol Biomaterial Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
6.2 Global Injectable Polyethylene Glycol Biomaterial Consumption Value by Application (2021-2032)
6.3 Global Injectable Polyethylene Glycol Biomaterial Average Price by Application (2021-2032)

7 North America

7.1 North America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
7.2 North America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
7.3 North America Injectable Polyethylene Glycol Biomaterial Market Size by Country
- 7.3.1 North America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Country (2021-2032)
- 7.3.2 North America Injectable Polyethylene Glycol Biomaterial Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
8.2 Europe Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
8.3 Europe Injectable Polyethylene Glycol Biomaterial Market Size by Country
- 8.3.1 Europe Injectable Polyethylene Glycol Biomaterial Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Injectable Polyethylene Glycol Biomaterial Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Market Size by Region
- 9.3.1 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Injectable Polyethylene Glycol Biomaterial Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
10.2 South America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
10.3 South America Injectable Polyethylene Glycol Biomaterial Market Size by Country
- 10.3.1 South America Injectable Polyethylene Glycol Biomaterial Sales Quantity by Country (2021-2032)
- 10.3.2 South America Injectable Polyethylene Glycol Biomaterial Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Market Size by Country
- 11.3.1 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Injectable Polyethylene Glycol Biomaterial Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Injectable Polyethylene Glycol Biomaterial Market Drivers
12.2 Injectable Polyethylene Glycol Biomaterial Market Restraints
12.3 Injectable Polyethylene Glycol Biomaterial Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Injectable Polyethylene Glycol Biomaterial and Key Manufacturers
13.2 Manufacturing Costs Percentage of Injectable Polyethylene Glycol Biomaterial
13.3 Injectable Polyethylene Glycol Biomaterial Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Injectable Polyethylene Glycol Biomaterial Typical Distributors
14.3 Injectable Polyethylene Glycol Biomaterial Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Injectable Polyethylene Glycol Biomaterial market size was valued at US$ 211 million in 2025 and is forecast to a readjusted size of US$ 384 million by 2032 with a CAGR of 8.9% during review period.
Injectable polyethylene glycol (PEG) biomaterials refer to biomedical materials—primarily composed of PEG and its derivatives—that are formed through crosslinking, modification, or compounding, enabling them to be administered via injection and exert localized effects within the body. Common forms include PEG hydrogels, PEG crosslinked networks, PEG-based drug delivery carriers, and tissue engineering scaffolds. These materials typically exhibit excellent hydrophilicity, biocompatibility, tunable degradability, and low immunogenicity. Once inside the body, they can form gels or stable structures, finding application in scenarios such as sustained drug release, cell delivery, tissue repair, wound healing, postoperative adhesion prevention, soft tissue augmentation, and medical sealing. Consequently, they serve as critical functional materials in the fields of regenerative medicine, minimally invasive therapies, and precision drug delivery.
The upstream segment of the Injectable polyethylene glycol (PEG) biomaterials industry chain primarily encompasses medical-grade PEG, functionalized PEG derivatives (such as PEGDA, PEGMA, 4-arm PEG, NHS-PEG, MAL-PEG, SH-PEG, etc.), crosslinking agents, photoinitiators, buffer salts, active pharmaceutical ingredients or cytokines, sterile packaging materials, and medical-grade manufacturing equipment. The midstream segment focuses on the formulation design, crosslinking modification, sterile filling, sterilization validation, and quality control of PEG-based injectable hydrogels, in-situ gelling systems, sustained-release drug carriers, cell delivery scaffolds, medical sealants, anti-adhesion materials, and soft tissue fillers. The downstream segment primarily targets hospitals, plastic and reconstructive surgery departments, general surgery, orthopedics, dentistry, wound care centers, drug delivery enterprises, regenerative medicine companies, and research institutions. The core value of this industry chain lies not in standard PEG raw materials, but rather in medical-grade modified PEG, controllable crosslinking technologies, in-vivo degradation performance, clinical safety, and regulatory approval capabilities. In terms of gross margins, standard PEG raw materials typically yield lower margins, ranging from approximately 20% to 35%.
In 2025, the average price of Injectable polyethylene glycol (PEG) biomaterials is projected to be $150 per kilogram, with a sales volume of 1,306 tons and a total production capacity of 1,865 tons.
Injectable polyethylene glycol (PEG) biomaterials constitute a class of high-end functional medical materials; they are not merely simple extensions of standard PEG raw materials, but rather represent a biomaterial platform defined by core values such as injectability, in-situ gelation, biodegradability, drug-loading capacity, and tissue-repairing capabilities. Driven by increasing demand in fields such as minimally invasive therapy, regenerative medicine, precision drug delivery, postoperative adhesion prevention, wound healing, and soft tissue augmentation, PEG-based injectable hydrogels demonstrate promising application prospects. They are particularly well-suited for use as sustained-release drug carriers, cell delivery scaffolds, and medical sealants or anti-adhesion agents. However, this field is characterized by high technical barriers and stringent regulatory thresholds; consequently, product competition centers not on the cost of the raw PEG materials, but rather on the design of crosslinking systems, biocompatibility, controllable degradation, clinical safety, sterilization stability, and regulatory approval capabilities. Overall, while the market for injectable PEG biomaterials remains in its growth phase, it is distinguished by high unit prices, high gross margins, and significant potential for clinical translation—marking a pivotal direction for the evolution of PEG materials from basic chemical commodities into high-value-added medical devices and drug delivery platforms.
This report is a detailed and comprehensive analysis for global Injectable Polyethylene Glycol Biomaterial market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Injectable Polyethylene Glycol Biomaterial market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Injectable Polyethylene Glycol Biomaterial market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Injectable Polyethylene Glycol Biomaterial market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/kg), 2021-2032
Global Injectable Polyethylene Glycol Biomaterial market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Injectable Polyethylene Glycol Biomaterial
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Injectable Polyethylene Glycol Biomaterial market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BASF, Dow, Croda Pharma, Clariant, KLK Kolb, India Glycols, Indorama Ventures, SABIC, INEOS Oxide, Liaoning Oxiranphex, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Injectable Polyethylene Glycol Biomaterial market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Fast-Setting Type (Seconds – 1 Minute)
Medium-Setting Type (1–10 Minutes)
Slow-Setting Type (Over 10 Minutes)
Market segment by Molecular Weight
Low Molecular Weight PEG
Medium Molecular Weight PEG
High Molecular Weight PEG
Market segment by Degradability
Non-Degradable Type
Slowly Degradable Rype
Controllably Degradable Type
Rapidly Degradable Type
Market segment by Application
Biopharmaceutical Industry
Medical Aesthetics Industry
Implant Material Supporting Industry
Others
Major players covered
BASF
Dow
Croda Pharma
Clariant
KLK Kolb
India Glycols
Indorama Ventures
SABIC
INEOS Oxide
Liaoning Oxiranphex
Pharcos
Sanyo Chemical Industries
NOF Corporation
JenKem Technology
Creative PEGWorks
Laysan Bio
Polypure
Biopharma PEG Scientific
BroadPharm
Pharcos Speciality
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Injectable Polyethylene Glycol Biomaterial product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Injectable Polyethylene Glycol Biomaterial, with price, sales quantity, revenue, and global market share of Injectable Polyethylene Glycol Biomaterial from 2021 to 2026.
Chapter 3, the Injectable Polyethylene Glycol Biomaterial competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Injectable Polyethylene Glycol Biomaterial breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Injectable Polyethylene Glycol Biomaterial market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Injectable Polyethylene Glycol Biomaterial.
Chapter 14 and 15, to describe Injectable Polyethylene Glycol Biomaterial sales channel, distributors, customers, research findings and conclusion.

Buy now